Table 1 Baseline information of patients. ETN: etanercept; ADA: adalimumab; INF: infliximab; SEC: secukinumab
Patient number | Sex | Age | Baseline bDMARD | Baseline ESR(mm/h) | Baseline CRP(mg/L) | Baseline BASDAI | Baseline ASDAS-CRP |
|---|---|---|---|---|---|---|---|
1 | Female | 31 | ETN | 25 | 13.3 | 4.20 | 3.13 |
2 | Male | 25 | ETN | 33 | 36.1 | 4.60 | 3.72 |
3 | Female | 28 | ADA | 42 | 33.0 | 5.75 | 4.15 |
4 | Female | 22 | ADA | 38 | 22.2 | 4.35 | 3.34 |
5 | Male | 21 | INF | 46 | 64.8 | 6.80 | 4.93 |
6 | Male | 37 | SEC | 27 | 18.8 | 3.95 | 3.17 |
7 | Male | 30 | INF | 19 | 10.6 | 4.05 | 2.83 |
8 | Male | 42 | ETN | 46 | 28.0 | 4.10 | 3.46 |
9 | Male | 28 | INF | 53 | 31.1 | 7.75 | 4.89 |
10 | Female | 33 | SEC | 44 | 20.2 | 3.25 | 2.91 |
11 | Male | 26 | SEC | 22 | 22.7 | 4.60 | 3.50 |
12 | Male | 44 | ADA | 76 | 56.4 | 7.15 | 4.99 |
13 | Male | 33 | ADA | 49 | 34.3 | 4.95 | 4.17 |
14 | Male | 23 | ETN | 111 | 44.9 | 7.10 | 4.79 |
15 | Male | 26 | ADA | 43 | 20.6 | 4.15 | 3.30 |